PaxMedica, Inc. Common Stock (PXMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.14 Million USD | -52.25% |
| 2022 | -10.6 Million USD | -47.33% |
| 2021 | -7.19 Million USD | -29.32% |
| 2020 | -5.56 Million USD | -829.8% |
| 2019 | -598.6 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.69 Million USD | 15.87% |
| 2024 Q2 | -2.99 Million USD | 18.74% |
| 2023 Q2 | -3.35 Million USD | 16.81% |
| 2023 FY | -16.14 Million USD | -52.25% |
| 2023 Q1 | -4.03 Million USD | 18.9% |
| 2023 Q3 | -4.36 Million USD | -29.98% |
| 2023 Q4 | -4.38 Million USD | -0.5% |
| 2022 Q4 | -4.97 Million USD | -84.7% |
| 2022 Q3 | -2.69 Million USD | -190.6% |
| 2022 Q2 | -927.38 Thousand USD | 53.74% |
| 2022 Q1 | -2 Million USD | -11.91% |
| 2022 FY | -10.6 Million USD | -47.33% |
| 2021 Q2 | -1.97 Million USD | -15.27% |
| 2021 Q1 | -1.71 Million USD | 19.2% |
| 2021 FY | -7.19 Million USD | -29.32% |
| 2021 Q4 | -1.79 Million USD | -4.45% |
| 2021 Q3 | -1.71 Million USD | 13.25% |
| 2020 Q4 | -2.12 Million USD | -29.32% |
| 2020 Q3 | -1.64 Million USD | -7.49% |
| 2020 Q2 | -1.52 Million USD | -454.8% |
| 2020 FY | -5.56 Million USD | -829.8% |
| 2020 Q1 | -275.22 Thousand USD | 0.0% |
| 2019 Q1 | -114.37 Thousand USD | 0.0% |
| 2019 Q2 | -137.89 Thousand USD | -20.56% |
| 2019 FY | -598.6 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -3177.269% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -69.629% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 46.17% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 75.954% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -1.908% |
| Better Therapeutics, Inc. | -38.26 Million USD | 57.803% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 61.626% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -34.881% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 52.295% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 53.092% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 85.115% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -701.532% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 52.517% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 65.613% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -1080.74% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 19.028% |
| Molecular Templates, Inc. | -10.46 Million USD | -54.264% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -14.906% |
| NexImmune, Inc. | -29.19 Million USD | 44.694% |
| Orgenesis Inc. | -53.63 Million USD | 69.898% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 68.524% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -20594.554% |
| Scopus BioPharma Inc. | -11.71 Million USD | -37.819% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 96.799% |
| Statera Biopharma, Inc. | -98.34 Million USD | 83.583% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -134.057% |
| Trevena, Inc. | -35.28 Million USD | 54.247% |
| Vaxxinity, Inc. | -58.28 Million USD | 72.299% |
| Vaccinex, Inc. | -22.88 Million USD | 29.45% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -1442.083% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 68.151% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -122.294% |